First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

(MedPage Today) — Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
Approval was supported by findings from the TRANSCEND FL trial and stipulates…

Source link : https://www.medpagetoday.com/hematologyoncology/lymphoma/118859

Author :

Publish date : 2025-12-05 18:25:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

Large MRI Study Points to Sex and Age Differences in Knee Injuries

ACIP Backs ‘Shared Decision-Making’ on Hep B Vax Birth Dose

Related Posts

Bump Pay for Physicians Treating Medicare Patients, MedPAC Says

Fellowship Match Day: How Did Rheumatology Fare?

Resurrecting a Global Killer: ACIP’s Hep B Vote

Early Results Amaze for One-Time Dravet Syndrome Treatment

SBRT vs Standard RT: Which Offers a QoL Edge in NSCLC?

Cardiologists on Board With FDA’s Proposed Food Package Labels

Bump Pay for Physicians Treating Medicare Patients, MedPAC Says

Fellowship Match Day: How Did Rheumatology Fare?

Resurrecting a Global Killer: ACIP’s Hep B Vote

Early Results Amaze for One-Time Dravet Syndrome Treatment

SBRT vs Standard RT: Which Offers a QoL Edge in NSCLC?

Cardiologists on Board With FDA’s Proposed Food Package Labels

ACIP Backs ‘Shared Decision-Making’ on Hep B Vax Birth Dose

First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

Categories

Archives